We are a consortium of companies who work together to find, fund and develop bioscience discoveries into life-changing medical innovations – and take them to the people who need them most.
Our scientific team identifies scientific discoveries from laboratories all over the world that have the potential to have life-changing impact.
Our corporate advisory and investment banking teams work together to translate scientific milestones into value creation events, creating financial instruments and corporate structures that activate commercial value.
Our commercialization team partners with healthcare providers and unlocks regulatory pathways to take the discovery to the people who need it.
2019
The iQ Group Global acquires TEX Core, an anti-cancer drug platform
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine
2018
China patent granted for Saliva Glucose Biosensor
2017
US patent granted for Saliva Glucose Biosensor
2016
The iQ Group Global accelerated the development of the Saliva Glucose Biosensor
iQ Capital incorporated in the USA
Series 8 Fund launched
FarmaForce wins Sales Team of the Year at PRIME Awards
iQ Capital incorporated in the USA
Series 8 Fund launched
FarmaForce wins Sales Team of the Year at PRIME Awards
2015
2014
Inception of CRC and FarmaForce
2012
iQnovate commences trading in the USA
2010
Inception of iQnovate
1997
Professor Paul Dastoor and University of Newcastle team began research into conducting polymers.